Patrys Issues New Shares Under Cleansing Notice, Confirms Regulatory Compliance

The latest announcement is out from Patrys Limited ( (AU:PAB) ).

Patrys Limited, an ASX‑listed biotechnology company, develops deoxymab cell‑penetrating antibody therapies targeting a variety of medical indications through its proprietary platform. The business is focused on advancing these novel biologic treatments to expand its therapeutic pipeline and strengthen its position in antibody‑based drug development.

The company has issued 466,666 new shares without a disclosure document under the Corporations Act, confirming it remains compliant with financial reporting and continuous disclosure obligations. Patrys also stated there is no excluded information requiring disclosure, indicating the share issue is a routine capital management action with no undisclosed material developments for investors.

More about Patrys Limited

Patrys Limited is an Australian biotechnology company listed on the ASX that focuses on developing its deoxymab platform of cell‑penetrating antibodies as therapies for a range of different medical indications. The company is advancing these antibody‑based treatments to address unmet needs across multiple disease areas, leveraging its proprietary technology platform to build a pipeline of novel therapeutics.

Average Trading Volume: 548,437

Technical Sentiment Signal: Strong Sell

Current Market Cap: A$18.19M

For detailed information about PAB stock, go to TipRanks’ Stock Analysis page.